Showing results (51-60 of 67) with videos related to
Sort By:
Pageof 7
Cancer|January 20, 2011
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)Athanassios Argiris, Musie Ghebremichael, Barbara Burtness, et al.Psychoneuroendocrinology|January 1, 1989
Hypothalamo-pituitary-adrenal activity in endogenously depressed post-traumatic stress disorder patientsU Halbreich, J Olympia, S Carson, et al.Journal of Biological Response Modifiers|April 1, 1990
The effect of a bacterial vaccine on tumors and the immune response of ICR/Ha miceH F Havas, G Schiffman, B Bushnell, et al.The Behavior Analyst|April 6, 2012
The right to effective behavioral treatmentR Van Houten, S Axelrod, J S Bailey, et al.Journal of Applied Behavior Analysis|January 1, 1988
The right to effective behavioral treatmentR Van Houten, S Axelrod, J S Bailey, et al.American Journal of Clinical Oncology|July 9, 2016
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck CancerPeter H Ahn, Mitchell Machtay, Pramila R Anne, et al.Seminars in Radiation Oncology|March 28, 2002
Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapyMaria Werner-Wasik, Rita S Axelrod, David P Friedland, et al.Clinical Lung Cancer|January 15, 2004
Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapyM Werner-Wasik, R S Axelrod, D P Friedland, et al.Journal of Immunological Methods|March 13, 2024
Selection of positive controls and their impact on anti-drug antibody assay performanceJoshua A Weiner, Harini Natarajan, Calum J McIntosh, et al.International Journal of Radiation Oncology, Biology, Physics|January 17, 2012
Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignanciesGregory J Kubicek, Rita S Axelrod, Mitchell Machtay, et al.Pageof 7